• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

lindam@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-6826-6014

Prof Linda Mileshkin

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

531 Scholarly works
21 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
    DOI: 10.1016/j.ijgc.2026.104556
  • 2026

    Journal article

    ROSELLA (GOG3073, engotov72, APGOT-OV10): a phase 3 study of relacorilant nab-paclitaxel in patients with platinum-resistant ovarian cancer
    DOI: 10.1016/j.ijgc.2025.104426
  • 2020

    Research grants (ARC, NHMRC, MRFF)

    Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
  • 2020

    Research grants (ARC, NHMRC, MRFF)

    Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial
  • 2020

    Research Grant

    ProTreat: An Adaptive and Rapid Implementation Trial of Novel Therapies to Prevent and Treat COVID19 Infection in High Risk Cancer Patients
  • 2015

    Journal article

    Whole-genome characterization of chemoresistant ovarian cancer
    DOI: 10.1038/nature14410
  • 2013

    Journal article

    Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
    DOI: 10.1002/path.4251
Linda Mileshkin

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinomas
    DOI: 10.1016/j.ijgc.2025.102890
  • 2026

    Journal article

    Survival and patterns of failure in small cell neuroendocrine carcinoma of the cervix treated with definitive chemoradiotherapy
    DOI: 10.1016/j.ijgc.2025.102874
  • 2025

    Journal article

    762MO Clinical whole genome and transcriptome sequencing for cancer of unknown primary: An Australian prospective observational study
    DOI: 10.1016/j.annonc.2025.10.1177
  • 2025

    Journal article

    Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin
    DOI: 10.1186/s12885-025-13506-4
  • 2025

    Journal article

    Introduction to the 2024 Consensus Guidelines for the Management of Neutropenic Fever in Patients with Cancer: Principles & Practice of Neutropenic Fever
    DOI: 10.1111/imj.70237
  • 2025

    Journal article

    Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial
    DOI: 10.1097/OGX.0000000000001475
  • 2025

    Journal article

    Steering Committee Members.
    DOI: 10.1111/imj.70323
  • 2025

    Journal article

    EXPLORING TRANSCRIPTIONAL SUBTYPES AND IMMUNE MARKERS IN BEACON; PHASE II STUDY OF ATEZOLIZUMAB, BEVACIZUMAB, COBIMETINIB IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
    DOI: 10.1016/j.ijgc.2025.102500

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224